Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical CLS003 first-in-human study in adults with cutaneous warts
NL-OMON41213Phase 1Active, not recruiting
- Sponsor
- Biofrontera
- Start
- Mar 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of digoxin and furosemide in verruca and human papillomavirus infection, sponsored by Biofrontera. Primary endpoints: Systemic exposure of digoxin and furosemide and Safety and tolerability. Started Mar 2014; status: active, not recruiting.
02
Drugs
digoxinfurosemide
03
Conditions
verrucahuman papillomavirus infection
Beyond the preview
Go deeper on NL-OMON41213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41213.